Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer
Authors:
- 1 October 1997
- journal article
- case report
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 20 (9) , 566-568
Abstract
Treatment of prostatic cancer with GnRH agonist is a medical alternative to surgical castration, although hyperstimulation of the tumor can occur. We describe an unusual unwanted effect of such a treatment which unmasked a clinically silent gonadotroph adenoma. A 62-year-old man developed after the first injection of leuprorelin-depot a sudden intracranial hypertension, which was related to apoplexy of an unknown pituitary adenoma. Its gonadotroph origin was recognized after surgery by immunocytochemistry. Retrospectively, the tumor was shown to secrete in vivo both FSH and LH when on therapy with the agonist, demonstrating the lack of desensitization. Testosterone levels were also markedly and sustainly high when on therapy, a particularly unwanted effect in prostatic cancer. As gonadotroph adenomas occur in men in the same age group as prostatic cancer, the question is raised whether hormonal testing and pituitary imaging should be performed before starting a therapy with GnRH agonist in men.Keywords
This publication has 13 references indexed in Scilit:
- Lack of effect of a gonadotropin-releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma.The Journal of Clinical Endocrinology & Metabolism, 1996
- Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma.The Journal of Clinical Endocrinology & Metabolism, 1995
- Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormoneClinical Endocrinology, 1993
- Evaluation of 29 Monoclonal and Polyclonal Antibodies Used in the Diagnosis of Pituitary AdenomasPathology - Research and Practice, 1991
- Recognition of Gonadotroph Adenomas in WomenNew England Journal of Medicine, 1991
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- Apoplexy of a pituitary adenoma after dynamic testing with gonadotropin-releasing hormoneThe American Journal of Medicine, 1989
- Gonadotropin andα-Subunit Responses to Chronic Gonadotropin-Releasing Hormone Analog Administration in Patients With Glycoprotein Hormone- Secreting Pituitary Tumors*The Journal of Clinical Endocrinology & Metabolism, 1989
- Gonadotropin-Releasing Hormone Agonists Are Unsuccessful in Reducing Tumoral Gonadotropin Secretion in Two Patients With Gonadotropin-Secreting Pituitary AdenomasThe Journal of Clinical Endocrinology & Metabolism, 1988
- Infarction of FSH-secreting pituitary adenomaEuropean Journal of Endocrinology, 1984